Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG002 in HER2-Positive Advanced Solid Tumors and Gastric/GEJ Cancer
NCT04492488Phase 2Active, not recruiting
- Sponsor
- Hangzhou Miracogen
- Start
- May 2021
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of MRG002 in HER2-positive solid tumor, gastric cancer (GC) and gastroesophageal junction cancer (2 arms), sponsored by Hangzhou Miracogen. Primary endpoints: Maximum Tolerated Dose, Recommended Phase II Dose and 2 more. Started May 2021; status: active, not recruiting.
02
Drugs
MRG002
03
Conditions
HER2-positive solid tumorgastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT04492488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04492488.